PRODUCT – Page 7

Vertex Pharmaceuticals Surpasses Q3 Expectations, Boosts Annual Revenue Forecast on Strong Cystic Fibrosis Sales

6 months ago talkbio0Tagged Casgevy, Cystic Fibrosis, earnings, full-year, Genetic Therapy, revenue guidance, Suzetrigine, Trikafta sales, vanzacaftor triple, VX-548

Vertex Pharmaceuticals, Q3 2024 earnings, Cystic fibrosis treatments, Trikafta sales, Full-year revenue guidance, Genetic therapies, Vanzacaftor triple, Suzetrigine (VX-548), Casgevy

Viking Therapeutics’ Oral Weight Loss Drug VK2735 Shows Promising Phase 1 Results

6 months ago talkbio0Tagged GLP-1/GIP Dual Agonist, Obesity, oral weight loss drug, phase 1 trial, VK2735

VK2735, Viking Therapeutics, oral weight loss drug, GLP-1/GIP dual agonist, obesity treatment, Phase 1 trial results

Kymera Therapeutics Shifts Focus to Immunology, Scaling Back Oncology Efforts

6 months ago talkbio0Tagged Immunology, IRAK4 gene, Kymera, Neoplasms, Protein Degradation, Metabolic, STAT6, TYK2 gene

Kymera Therapeutics, Immunology, Oncology, Targeted Protein Degradation, IRAK4, STAT6, TYK2

ESSA Pharma Terminates Masofaniten Development After Phase 2 Trial Failure in Prostate Cancer

6 months ago talkbio0Tagged Clinical Trial Termination, enzalutamide, ESSA, Malignant neoplasm of prostate, masofaniten, Pharma, Phase 2 trial

ESSA Pharma, Masofaniten, Prostate Cancer, Phase 2 Trial, Enzalutamide, Xtandi, Clinical Trial Termination

European Commission Imposes €463 Million Fine on Teva for Anti-Competitive Practices in MS Drug Market

6 months ago talkbio0Tagged Commission, competition, Copaxone, Dominance, European (ethnic group), Market, Mississippi (geographic location), MS, tactics, Teva

Teva, European Commission, fine, MS drug, competition tactics, Copaxone, market dominance

Amgen Refocuses Pipeline, Prioritizes Obesity Therapies Amid Strategic Cuts

6 months ago talkbio0Tagged amgen, MariTide, Obesity, Phase 3 program, pipeline, strategic refocus

Amgen, Obesity Therapies, Pipeline Cuts, Strategic Refocus, MariTide, Phase 3 Program

Iambic Therapeutics Enhances AI Suite with “Enchant” for Predictive Preclinical Drug Development

6 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, clinical success, Drug Discovery, Enchant, Iambic, preclinical predictive powers, Prediction

Iambic Therapeutics, AI, Enchant, preclinical predictive powers, drug discovery, clinical success prediction

Roche Revisits Dyno for AAV Technology with $50M Upfront Payment

6 months ago talkbio0Tagged AAV, AAVS1 gene, Dyno, gene therapy, Neurological diseases, Roche (company), strategic partnership, Technology

Roche, Dyno Therapeutics, AAV technology, gene therapy, neurological diseases, strategic partnership

Starboard Value Targets Kenvue for Revitalization Following $1B Stake in Pfizer

6 months ago talkbio0Tagged activist investor, Consumer, Health, Johnson & Johnson, Kenvue, Pfizer, Pfizer/, Starboard Value

Starboard Value, Kenvue, Johnson & Johnson, Pfizer, activist investor, consumer health, pharmaceuticals

Seaport Therapeutics Secures $225M Series B Funding to Revolutionize Neuropsychiatric Medicines

6 months ago talkbio0Tagged clinical-stage pipeline, Depressive disorder, Glyph technology platform, neuropsychiatric medicines, Seaport, Series B

Seaport Therapeutics, Series B funding, neuropsychiatric medicines, Glyph technology platform, clinical-stage pipeline, major depressive disorder, generalized anxiety disorder.